Anson K. Abraham, Ph.D.
Affiliations: | 2010 | Pharmaceutical Sciences | State University of New York, Buffalo, Buffalo, NY, United States |
Google:
"Anson Abraham"Parents
Sign in to add mentor| Donald E. Mager | grad student | 2010 | SUNY Buffalo | |
| (Pharmacokinetics and pharmacodynamics of selected compounds affecting bone homeostasis.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Tang H, Shah K, Steinmetz T, et al. (2019) Development and validation of a multiplexed drug level assay in support of combination biologics therapy clinical studies. Journal of Pharmaceutical and Biomedical Analysis. 171: 204-211 |
| Tiwari A, Abraham AK, Harrold JM, et al. (2017) Erratum to: Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling. The Aaps Journal |
| Tiwari A, Abraham AK, Harrold JM, et al. (2016) Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling. The Aaps Journal |
| Visintin A, Knowlton K, Tyminski E, et al. (2015) Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature. Molecular Cancer Therapeutics |
| Chudasama VL, Zutshi A, Singh P, et al. (2015) Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies. Journal of Pharmacokinetics and Pharmacodynamics. 42: 1-18 |
| Singh AP, Krzyzanski W, Martin SW, et al. (2015) Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition. The Aaps Journal. 17: 389-99 |
| Harrold JM, Abraham AK. (2014) Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment. Journal of Pharmacokinetics and Pharmacodynamics. 41: 141-51 |
| Abraham AK, Maurer TS, Kalgutkar AS, et al. (2011) Pharmacodynamic model of parathyroid hormone modulation by a negative allosteric modulator of the calcium-sensing receptor. The Aaps Journal. 13: 265-73 |
| Abraham AK, Kagan L, Kumar S, et al. (2010) Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in mice. The Journal of Pharmacology and Experimental Therapeutics. 334: 327-32 |
| Kagan L, Abraham AK, Harrold JM, et al. (2010) Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharmaceutical Research. 27: 920-32 |